The objective of this secondary analysis was to explore differences in baseline clinical characteristics and opioid re placement therapy treatment outcomes by type (heroin, opioid analgesic [OA], or combined [heroin and OA]) and route (injector or non-injector) of opioid use. Method: A total of 1,269 participants (32.2% female) were randomized to receive one of two study medications (methadone or buprenorphine/naloxone [BUP]). Of these, 731 participants completed the 24-week active medication phase. Treatment outcomes were opioid use during the final 30 days of treatment (among treatment completers) and treatment attrition. Results: Non-opioid substance dependence di agnoses and injecting differentiated heroin and combined users from OA users. Non-opioid substance dependence diagnoses and greater heroin use differentiated injectors from non-injectors. Further, injectors were more likely to be using at end of treatment compared with non-injectors. OA users were more likely to complete treatment compared with heroin users and combined users. Non-injectors were more likely than injectors to complete treatment. There were no interactions between type of opioid used or injection status and treatment assignment (methadone or BUP) on either opioid use or treatment attrition. Conclusions: Findings indi cate that substance use severity differentiates heroin users from OA users and injectors from non-injectors. Irrespective of medication, heroin use and injecting are associated with treatment attrition and opioid misuse during treatment. These results have particular clinical interest, as there is no evidence of superiority of BUP over methadone for treating OA users versus heroin users. (J. Stud. Alcohol Drugs, 74, 605-613, 2013) 
at treatment for substance use disorder, have fewer years of opioid use, and are less likely to have drug-related medical complications than heroin users (Moore et al., 2007) . Heroin users are more likely to be involved with the legal system (Banta-Green et al., 2009) , be older, be African American, have a history of attempts at treatment for substance use disorder, and report using other drugs (Wu et al., 2011) . Compared with heroin users, combined (OA and heroin) users are more likely to be White, and compared with OA users, combined users are more likely to have more attempts at treatment for substance use disorder (Moore et al., 2007) . Combined users also report more polydrug use and are more likely to have multiple substance use disorder diagnoses, including a lifetime opioid use disorder diagnosis (Wu et al., 2011) . Overall, OA users tend to present with a less severe opioid dependence compared with heroin users. Heroin use is often associated with a longer drug-using history com pared with OA use, which may partially account for more severe opioid dependence seen in heroin users.
Compared with heroin injectors, non-injectors are more likely to be female (Puigdollers et al., 2004) , younger, and employed and have higher levels of education, lower levels of crime, shorter heroin-using histories, fewer symptoms of dependence, fewer attempts at treatment for substance use disorder, and fewer overdoses (Darke et al., 2004) . Conversely, compared with non-injectors, heroin injectors are more likely to be homeless, unemployed, long-time users, and younger at first heroin use and to have initi ated heroin use through intravenous routes (Neaigus et al., 2001) . Injectors are also more likely to report a history of incarceration and arrests (Young and Havens, 2012) . In comparison to injectors, non-injectors have a more stable socioeconomic status and fewer adverse effects because of their opioid use. Using opioids in a manner other than oral use seems to put the user at risk for not only medical complications but progression toward more severe opioid dependence as well. Not surprisingly, compared with OA users, heroin users are more likely to have a history of in jecting opioids and sharing needles (Brands et al., 2004) . However, there are recent reports of opioid users initiating injection use with an OA before any heroin use (Young and Havens, 2012) .
Although research has examined the association between treatment outcomes and type of ORT (e.g., buprenorphine/ naloxone [BUP] , methadone), little information is available regarding this association and type of opioid used or injec tion status. Examining BUP treatment outcomes, OA users are more likely to complete treatment successfully, remain in treatment longer, have an improved treatment response, and have a higher percentage of opioid-negative urine samples compared with heroin users (Moore et al., 2007) . Specifi cally addressing ORT with methadone maintenance therapy, a history of injecting was associated with ongoing substance use during treatment (Neufeld et al., 2008) .
The literature has examined treatment outcomes in metha done maintenance therapy and BUP maintenance therapy by type of opioid used or injection status, but no studies, to our knowledge, have concurrently examined both ORT medications and type and route of opioid use. Because of the potential associations among type of opioid, route of use, and treatment outcomes, particularly relevant with the cur rent high rates of OA use documented in the United States, it is important to better understand these relationships. The objective of this secondary analysis was to examine differ ences in clinical characteristics and associated treatment outcomes by type and route of opioid use and any potential interactions with ORT treatment assignment in individuals seeking treatment for opioid dependence. These data come from a large, multisite safety trial comparing liver health of participants randomly assigned to 24 weeks of treatment with either methadone or BUP under the auspices of the National Institute on Drug Abuse National Drug Abuse Treatment Clinical Trials Network.
Method

Design
The main study was a randomized, open-label, multi center, Phase 4 study to assess liver function in participants randomized to medication condition (methadone, BUP). Randomization was stratified within site according to normal versus abnormal screening liver-function test results (see main outcome results, Saxon et al., 2013) . The institutional review boards at participating sites approved the study, and participants provided written informed consent. , 2000) . Medical ineligibility included having an alanine amino transferase or aspartate amino transferase value greater than five times the upper limit of normal or an alkaline phosphatase value greater than three times the upper limit of normal, having an allergy to study drug, being pregnant or lactating, or hav ing a medical/psychiatric condition that would make study participation difficult or unsafe. Participants with a DSM IV-TR diagnosis of current alcohol, benzodiazepine, or other sedative-hypnotic dependence were excluded if they required immediate medical attention. Those with legal or other is sues that could result in early termination and those who had recently participated in a treatment study for a substance use disorder were also excluded.
Participants
Because of higher dropout in the BUP condition, the initial randomization scheme of 1:1 (BUP:methadone) was changed to 2:1 in December 2007, 18 months after study initiation. Participants completed follow-up assessments through August 2010.
Measures
Measures used in the current secondary analyses included information collected at screening/baseline as well as study outcome data as described below. Demographic informa tion collected included participants' age, gender, race, and ethnicity.
Clinical characteristics. Initially, DSM-IV-TR substance use diagnoses were established using the Substance Abuse subsections (Alcohol and Drug) of the Composite Interna tional Diagnostic Interview (CIDI Version 2.1; World Health Organization, 1997) (n = 175). The CIDI was replaced with the DSM-IV Checklist (n = 1,094) to reduce length of the assessment battery. The Risk Behavior Survey (Booth et al., 1993) collected drug use histories including substance use and route of use in the previous 30 days. The Fagerström Test for Nicotine Dependence (Heatherton et al., 1991) , a six-item self-report questionnaire, assessed severity of nicotine dependence. The Short Form 36-item Health Survey (Ware and Sherbourne, 1992) , a self-report instrument, as sessed each of eight health concepts: physical functioning, physical role limitations, bodily pain, social functioning, emotional role limitations, general mental health, vitality, and general health perceptions.
Procedures
Eligible participants were stratified by site and liver-func tion results (normal vs. abnormal) and randomized to either open-label methadone or BUP. Compensation was provided in accordance with local site policies but typically included a maximum of $300 for completing assessments across the entire study.
Treatment
Medication induction and stabilization followed guide lines for methadone and BUP pharmacotherapy for 24 weeks of treatment, followed by a taper, with study completion by Week 32 (see Saxon et al., 2013 , for detailed descriptions of the medication phase). Weekly assessments included urine drug screens and adverse event monitoring, and self-reported drug use data were collected every 4 weeks.
Buprenorphine/naloxone. BUP was provided as a com bination sublingual tablet containing both buprenorphine and naloxone. Following a 3-day induction, patients were stabilized on BUP up to 32 mg per day. Recommended dose changes were made in 2 mg to 8 mg increments, with daily doses ranging from 2 mg to 32 mg. The mean maximum daily BUP dose was 22.1 mg (SD = 8.2; Mdn = 24 mg). BUP was provided daily or 3 times weekly in accordance with pertinent federal and state rules about take-home dosing.
Methadone. Methadone was purchased and obtained directly by each clinical site. Following a 3-day induction, flexible dosing was used during the stabilization period. No specific maximum daily dose was set for methadone. The mean daily maximum methadone dose was 93.2 mg (SD = 42.2; Mdn = 90 mg). Methadone was dispensed daily, although take-home medication was provided for clinic closures, holidays, weekends, and in accordance with clinic policies and procedures.
Statistical analysis
For these analyses, the two groups of interest were defined by opioid type used and injection status. Based on opioid use in the previous 30 days, three opioid-type groups were identified: heroin only, OA only (e.g., oxyco done, hydrocodone), and combined (heroin and OA), and two injection-status groups were identified: injectors and non-injectors.
Our primary outcome measures were abstinence from opi oids (heroin and OA) and treatment attrition. Abstinence was defined as self-report of no opioid use in the 30 days before the end of maintenance therapy (i.e., Week 24). Based on attendance records, days in study were calculated and used in the examination of treatment attrition.
Bivariate comparisons were calculated between baseline clinical characteristics and the three opioid-type groups (heroin, OA, and combined), and between the two injectionstatus groups (injector and non-injector) using chi-square tests for categorical variables and two-tailed t tests for continuous variables. Significant predictors from bivariate analyses were included in multivariate analyses for opioid type and injection status. Multinomial logistic regression was used to examine associations of baseline clinical char acteristics with the three opioid-type groups. The validity of the independence of irrelevant alternatives assumption for these three groups was confirmed using Hausman (1978) and Small and Hsiao (1985) tests. Subsequently, logistic re gression was used to examine associations between baseline clinical characteristics and the two injection status groups.
After examining group differences in baseline clinical characteristics, we examined whether type of opioid and injection status moderated treatment outcomes. The out comes of interest were abstinence, measured as any opioid use (heroin or OA) in the previous 30 days (yes/no) at end of treatment (i.e., Week 24); and time to dropout, measured in days.
Logistic regression was used to examine whether baseline clinical characteristics, opioid type, or injection status pre dicted abstinence at end of treatment. In addition, we exam ined two-way and three-way interactions between treatment assignment (BUP or methadone), opioid type, and injection status. Logistic regression analyses include only participants who completed the 24-week medication phase. Treatment assignment, age, and gender were included as covariates. Finally, Cox regression was used to examine the independent associations between type of opioid or injection status and treatment attrition. Interaction with treatment assignment and either opioid type or injection status on attrition rates was also examined. Treatment assignment, age, and gender were included as covariates.
Results
Participants
A total of 1,920 participants consented; 1,269 met eligi bility criteria and were randomized and inducted on study medication (n BUP = 529 participants completed the 24-week active medication phase (n BUP = 340, n methadone = 391). Unless otherwise noted, the results reported in these analyses reflect the 1,269 random ized participants for baseline analyses.
Baseline clinical characteristics
Type of opioid. Group differences by type of opioid (heroin, OA, and combined) are shown in Table 1 . Bivariate results and post hoc tests indicated significant differences between the groups on clinical characteristics. Compared with OA users, heroin users were more likely to be older, non-White, Hispanic, cocaine dependent, non-sedative dependent, and injectors. Relative to OA users, combined users were more likely to be older, non-White, Hispanic, cocaine dependent, sedative dependent, and injectors and to report fewer days of OA use. Compared with heroin users, combined users were more likely to be sedative dependent and non-injectors and to report fewer days of heroin use, less bodily pain, and less emotional well-being.
Injection status. Group differences in baseline character istics by injection status are presented in Table 2 . Bivariate results indicated that compared with non-injectors, injectors were more likely to be male, older, Hispanic, and cocaine de pendent; to have ever used heroin; and to report fewer days of OA use and more days of heroin use. Non-injectors were significantly more likely to have ever used OA compared with injectors.
Multivariate results
The significant bivariate variables were entered as predic tors into a multinomial logistic regression model. Relative to heroin users, OA users were significantly more likely to be 
Treatment outcomes
Continued opioid use. Any opioid use (heroin or OA) at end of treatment (use or no use) was compared with baseline characteristics and opioid-type and injection-status groups (Table 3) . As noted above, 731 participants completed the 24-week assessments and are included in these analyses. Bi variate results indicated that those who were African Ameri can were more likely to be using opioids, and those who were cannabis dependent were less likely to be using opioids at end of treatment. Those who reported ever using heroin with a greater number of days of heroin use at baseline were more likely to be using opioids, and those who reported a greater number of days of OA use at baseline were less likely to be using opioids at end of treatment. Injectors were more likely to be using opioids at end of treatment compared with non-injectors. Among the opioid-type groups, OA users were less likely to be using at end of treatment compared with heroin and combined users. Controlling for treatment assignment, age, and gender, those who were cannabis dependent were significantly less likely to be using opioids at end of treatment (aOR = 0.48, 95% CI [0.25, 0.92]), and compared with non-injectors, injectors were significantly more likely to be using opioids at end of treatment (aOR = 1.98, 95% CI [1.41, 2.80]). Last, there were no statistically significant two-way or three-way interactions among treatment assignment, type of opioid, and injection status on opioid use at end of treatment. In other words, there was no effect of treatment by type of opioid used or injection status on opioid use outcome among treat ment completers. In examining the three-way interaction, only three OA users reported injection. To determine the impact of these two small cell sizes on the model, a sensitiv ity analysis was performed (collapsing the OA injectors with the non-injectors for BUP and methadone by omitting those interaction terms from the model); results were unchanged.
Treatment attrition. BUP participants were significantly less likely to complete treatment compared with those on methadone (OR = 0.38, 95% CI [0.31, 0.46] ). Because of this significant difference in attrition rates, treatment assign ment was included as a covariate in all Cox regressions; age and gender were also included as covariates in the exami nations of differential attrition rates for type of opioid and injection status. Results indicated that those who were older were significantly less likely to complete treatment (aOR = 0.98, 95% CI [0.97, 0.99] ). As shown in Figure 1 , compared with OA users, heroin users were significantly less likely to complete treatment (aOR = 0.56, 95% CI [0.40, 0.77]) . Similarly, compared with OA users, combined users were also significantly less likely to complete treatment (aOR = Furthermore, there were no significant two-way interac tions between treatment assignment and opioid type or treat ment assignment and injection status on attrition. In other words, there were similar factors influencing rates of attrition for those on BUP and those on methadone concerning type of opioid used or injection status.
Discussion
The purpose of this secondary analysis was to compare baseline clinical characteristics of opioid users and explore whether type of opioid used and injection status are associ ated with subsequent response to ORT (either methadone or BUP), with both opioid use at end of treatment and attrition as measures of treatment outcome. As a whole, this study extends prior findings by including combined opioid users and injection status in examining treatment response to BUP and methadone in a single study.
Not surprisingly, clinical differences emerged between our three types of opioid users. Heroin and combined users exhibited the more severe clinical presentation (i.e., more likely to have additional non-opioid substance dependence diagnoses and to be injectors). As has been reported previ ously (Nielsen et al., 2012) , exclusive OA users did report greater pain and emotional distress; however, these factors did not differentiate the three groups in multivariate analy ses. Rather, substance use severity is most salient. As with the results reported above, substance use severity rather than other clinical factors differentiates injectors from noninjectors. Compared with non-injectors, injectors are more likely to have used heroin and with greater frequency. Taken together, these findings support the assertion that heroin use and injecting are markers of clinical severity that may affect treatment response.
Indeed, lifetime heroin use predicts poorer treatment outcome compared with OA use. This finding supports previous reports indicating that heroin users are less likely to have successful treatment outcomes compared with OA users (Banta-Green et al., 2009; Brands et al., 2004; Moore et al., 2007) . For example, one study found that any heroin use increased risk of poor treatment response compared with no heroin use in a sample that was primarily dependent on OAs (Weiss et al., 2011) . As expected (Neufeld et al., 2008) , injection status predicts poor treatment response to methadone and BUP treatment. The poorer response associ ated with heroin use and history of injection in this report is irrespective of maintenance medication received. Notably, this study appears to be the first to directly compare metha done and BUP treatment responses for these groups. This suggests that, although other factors may drive medication selection (e.g., availability and patient preference), there is no evidence to indicate a differential outcome for methadone or BUP.
Similar to treatment response, there were significant dif ferences in attrition indicating poor treatment retention for heroin users and injectors. Consistent with previous findings (Brands et al., 2004; Moore et al., 2007) , heroin users are less likely to complete treatment compared with OA users. Similarly, injectors are less likely to complete treatment compared with non-injectors. These are particularly impor tant findings as retention in treatment is the best predictor of clinical outcomes (Corsi et al., 2009; Hutchinson et al., 2000; Weiss et al., 2011) . Finally, as with opioid use at end of treatment, these results were irrespective of treatment assignment.
It is important to note that our results indicate no signifi cant clinical advantage for BUP versus methadone in treating OA versus heroin users or non-injectors versus injectors for those who complete treatment. This is particularly interesting because, in the absence of empirical evidence, there may be a perception that OA users will respond more favorably to BUP. Our findings suggest that there is no superior treatment for OA users; receiving either ORT increases the probability of attaining a successful outcome. However, there may be other factors to consider when deciding on an ORT (e.g., provision through an individual health care provider, as is possible with BUP, versus through a structured methadone clinic). This is particularly important given the higher attri tion rate observed in BUP patients compared with metha done patients. However, the reasons for this dropout do not appear to be related to type of opioid or injection status.
As with any secondary analysis, there are limitations. Opioid type, injection status, and opioid use at end of treatment were based on self-report. Except for treatment assignment, these analyses considered baseline character istics. In-treatment factors may have also affected outcome. Information regarding treatment response, defined for these analyses as opioid use in the previous 30 days, was only available for individuals who attended their final treatment visit at Week 24. Although the Risk Behavior Survey is a self-report instrument, evidence indicates that self-report is a reliable and valid measure of drug behaviors (Darke, 1998) . Finally, there was a higher dropout rate in the BUP compared with the methadone treatment condition.
Conclusion
To our knowledge, this is the first report that examines the role of type and route of opioid use on both methadone and BUP outcomes directly. It is also the first study to en able a direct comparison between BUP and methadone for OA users. The findings reported here add to the literature a large-scale examination of differences in treatment out comes for heroin versus OA users and for injectors versus non-injectors. Of particular interest is the finding that BUP does not appear to be superior to methadone for treating OA users.
In total, these findings indicate that heroin use and inject ing are significantly associated with poor treatment outcomes regardless of ORT medication, and this may be attributed to the progression in the disease state observed in heroin users and injectors. Clinically, this suggests that programs offering maintenance therapies may benefit from targeting retention efforts on heroin and injection users. Potential interventions could include assuring that medication doses are optimized (Strain et al., 1999) , using contingency management (Peirce et al., 2006) , or directing interventions to specific problem areas of individual patients (McLellan et al., 1993) .
